Michael J Pennington

US Patent:

8080523, Dec 20, 2011

Filed:

Oct 7, 2005

Appl. No.:

11/663398

Inventors:

Christine Beeton - Irvine CA, US
George K. Chandy - Laguna Beach CA, US
Michael William Pennington - Mount Laurel NJ, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 38/00
A61K 38/16
A61K 38/28
A61P 3/04
A61P 25/00
A61P 3/10
A61P 7/12

US Classification:

514 174, 514 69, 514 177

Abstract:

Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e. g. an atom, molecule, group, residue, compound, moiety, etc. ) that has an anionic charge. In some embodiments the chemical entity attached to the ShK toxin may comprise an amino acid residue. The ShK analogs may be administered to human or non-human animal subjects to cause inhibition of potassium channels or to otherwise treat diseases or disorders. In some embodiments, the chemical entity to which the ShK toxin is attached may be chosen to provide selective inhibition of certain potassium channels (e. g. , Kv1. 3 channels) over other potassium channels (e. g. , Kv1. 1 channels). In come embodiments, the chemical entity to which the ShK toxin is attached may include a fluorophore, thereby providing a fluorophore tagged ShK analog.

US Patent:

20120142600, Jun 7, 2012

Filed:

Nov 1, 2011

Appl. No.:

13/286939

Inventors:

Christine Beeton - Irvine CA, US
George K. Chandy - Laguna Beach CA, US
Michael William Pennington - Cherry Hill NJ, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

International Classification:

A61K 38/17
A61P 37/00

US Classification:

514 174

Abstract:

Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety, etc.) that has an anionic charge. The ShK analogs may be administered to human or non-human animal subjects to cause inhibition of potassium channels or to otherwise treat diseases or disorders. In some embodiments, the chemical entity to which the ShK toxin is attached may be chosen to provide selective inhibition of certain potassium channels (e.g., Kv1.3 channels) over other potassium channels (e.g., Kv1.1 channels). In come embodiments, the chemical entity to which the ShK toxin is attached may include a fluorophore and such fluorophore-tagged ShK analogs may be used in flow cytometry alone, or in conjunction with class II tetramers that can detect autoreactive cells.

US Patent:

20140027361, Jan 30, 2014

Filed:

Jun 13, 2013

Appl. No.:

13/916896

Inventors:

Michael PENNINGTON - Mission Viejo CA, US

Assignee:

LANCER CORPORATION - San Antonio TX

International Classification:

B01D 35/147

US Classification:

210120, 29428, 294261

Abstract:

A filtration system includes a filter assembly removably coupled with a manifold. The coupling of the filter assembly coupled with the manifold aligns an intake port of the filter assembly with an inlet tube of the manifold and communicates a flow tube of the filter assembly with an exit tube of the manifold. The filter assembly pushes a shut-off valve of the manifold from its normally closed position to its open position. Liquid then flows into the filter assembly from the inlet tube of the manifold and filtered liquid flows into exit tube of the manifold from the flow tube of the filter assembly. The filter assembly further pushes a pressure relief valve of the manifold from its normally open position to its closed position.